A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge

Katharine N. Bossart, Barry Rockx, Friederike Feldmann, Doug Brining, Dana Scott, Rachel LaCasse, Joan B. Geisbert, Yan Ru Feng, Yee Peng Chan, Andrew C. Hickey, Christopher C. Broder, Heinz Feldmann, Thomas Geisbert

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

In the 1990s, Hendra virus and Nipah virus (NiV), two closely related and previously unrecognized paramyxoviruses that cause severe disease and death in humans and a variety of animals, were discovered in Australia and Malaysia, respectively. Outbreaks of disease have occurred nearly every year since NiV was first discovered, with case fatality ranging from 10 to 100%. In the African green monkey (AGM), NiV causes a severe lethal respiratory and/or neurological disease that essentially mirrors fatal human disease. Thus, the AGM represents a reliable disease model for vaccine and therapeutic efficacy testing. We show that vaccination of AGMs with a recombinant subunit vaccine based on the henipavirus attachment G glycoprotein affords complete protection against subsequent NiV infection with no evidence of clinical disease, virus replication, or pathology observed in any challenged subjects. Success of the recombinant subunit vaccine in nonhuman primates provides crucial data in supporting its further preclinical development for potential human use.

Original languageEnglish (US)
Article number146ra107
JournalScience Translational Medicine
Volume4
Issue number146
DOIs
StatePublished - Aug 8 2012

Fingerprint

Hendra Virus
Nipah Virus
Cercopithecus aethiops
Subunit Vaccines
Glycoproteins
Synthetic Vaccines
Henipavirus
Malaysia
Human Development
Virus Diseases
Virus Replication
Primates
Disease Outbreaks
Vaccination
Vaccines
Pathology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. / Bossart, Katharine N.; Rockx, Barry; Feldmann, Friederike; Brining, Doug; Scott, Dana; LaCasse, Rachel; Geisbert, Joan B.; Feng, Yan Ru; Chan, Yee Peng; Hickey, Andrew C.; Broder, Christopher C.; Feldmann, Heinz; Geisbert, Thomas.

In: Science Translational Medicine, Vol. 4, No. 146, 146ra107, 08.08.2012.

Research output: Contribution to journalArticle

Bossart, KN, Rockx, B, Feldmann, F, Brining, D, Scott, D, LaCasse, R, Geisbert, JB, Feng, YR, Chan, YP, Hickey, AC, Broder, CC, Feldmann, H & Geisbert, T 2012, 'A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge', Science Translational Medicine, vol. 4, no. 146, 146ra107. https://doi.org/10.1126/scitranslmed.3004241
Bossart, Katharine N. ; Rockx, Barry ; Feldmann, Friederike ; Brining, Doug ; Scott, Dana ; LaCasse, Rachel ; Geisbert, Joan B. ; Feng, Yan Ru ; Chan, Yee Peng ; Hickey, Andrew C. ; Broder, Christopher C. ; Feldmann, Heinz ; Geisbert, Thomas. / A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge. In: Science Translational Medicine. 2012 ; Vol. 4, No. 146.
@article{9308efb4002a4b5bb715faa68f476d2f,
title = "A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge",
abstract = "In the 1990s, Hendra virus and Nipah virus (NiV), two closely related and previously unrecognized paramyxoviruses that cause severe disease and death in humans and a variety of animals, were discovered in Australia and Malaysia, respectively. Outbreaks of disease have occurred nearly every year since NiV was first discovered, with case fatality ranging from 10 to 100{\%}. In the African green monkey (AGM), NiV causes a severe lethal respiratory and/or neurological disease that essentially mirrors fatal human disease. Thus, the AGM represents a reliable disease model for vaccine and therapeutic efficacy testing. We show that vaccination of AGMs with a recombinant subunit vaccine based on the henipavirus attachment G glycoprotein affords complete protection against subsequent NiV infection with no evidence of clinical disease, virus replication, or pathology observed in any challenged subjects. Success of the recombinant subunit vaccine in nonhuman primates provides crucial data in supporting its further preclinical development for potential human use.",
author = "Bossart, {Katharine N.} and Barry Rockx and Friederike Feldmann and Doug Brining and Dana Scott and Rachel LaCasse and Geisbert, {Joan B.} and Feng, {Yan Ru} and Chan, {Yee Peng} and Hickey, {Andrew C.} and Broder, {Christopher C.} and Heinz Feldmann and Thomas Geisbert",
year = "2012",
month = "8",
day = "8",
doi = "10.1126/scitranslmed.3004241",
language = "English (US)",
volume = "4",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "146",

}

TY - JOUR

T1 - A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge

AU - Bossart, Katharine N.

AU - Rockx, Barry

AU - Feldmann, Friederike

AU - Brining, Doug

AU - Scott, Dana

AU - LaCasse, Rachel

AU - Geisbert, Joan B.

AU - Feng, Yan Ru

AU - Chan, Yee Peng

AU - Hickey, Andrew C.

AU - Broder, Christopher C.

AU - Feldmann, Heinz

AU - Geisbert, Thomas

PY - 2012/8/8

Y1 - 2012/8/8

N2 - In the 1990s, Hendra virus and Nipah virus (NiV), two closely related and previously unrecognized paramyxoviruses that cause severe disease and death in humans and a variety of animals, were discovered in Australia and Malaysia, respectively. Outbreaks of disease have occurred nearly every year since NiV was first discovered, with case fatality ranging from 10 to 100%. In the African green monkey (AGM), NiV causes a severe lethal respiratory and/or neurological disease that essentially mirrors fatal human disease. Thus, the AGM represents a reliable disease model for vaccine and therapeutic efficacy testing. We show that vaccination of AGMs with a recombinant subunit vaccine based on the henipavirus attachment G glycoprotein affords complete protection against subsequent NiV infection with no evidence of clinical disease, virus replication, or pathology observed in any challenged subjects. Success of the recombinant subunit vaccine in nonhuman primates provides crucial data in supporting its further preclinical development for potential human use.

AB - In the 1990s, Hendra virus and Nipah virus (NiV), two closely related and previously unrecognized paramyxoviruses that cause severe disease and death in humans and a variety of animals, were discovered in Australia and Malaysia, respectively. Outbreaks of disease have occurred nearly every year since NiV was first discovered, with case fatality ranging from 10 to 100%. In the African green monkey (AGM), NiV causes a severe lethal respiratory and/or neurological disease that essentially mirrors fatal human disease. Thus, the AGM represents a reliable disease model for vaccine and therapeutic efficacy testing. We show that vaccination of AGMs with a recombinant subunit vaccine based on the henipavirus attachment G glycoprotein affords complete protection against subsequent NiV infection with no evidence of clinical disease, virus replication, or pathology observed in any challenged subjects. Success of the recombinant subunit vaccine in nonhuman primates provides crucial data in supporting its further preclinical development for potential human use.

UR - http://www.scopus.com/inward/record.url?scp=84864851299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864851299&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3004241

DO - 10.1126/scitranslmed.3004241

M3 - Article

VL - 4

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 146

M1 - 146ra107

ER -